Astellas Pharma, Inc./ US04623U1025 /
| 2024-05-10 9:59:59 PM | Chg. -0.1800 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 9.7200USD | -1.82% | 145,881 Turnover: 822,120.3382 |
-Bid Size: - | -Ask Size: - | 25.77 bill.USD | - | - |
Fundamentals
| FY 2021 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | 67.08 JPY | - |
| EPS Diluted: | - JPY | - |
| Revenues per Share: | - JPY | - |
| Book Value per Share: | - JPY | - |
| Cash Flow per Share: | - JPY | - |
| Dividend per Share: | - JPY | - |
| Total | in mill. | |
| Revenues: | 1,296,163.00 JPY | - |
| Net Income: | 124,086.00 JPY | - |
| Operating Cash Flow: | 257,444.00 JPY | - |
| Cash and Cash Equivalents: | 315,986.00 JPY | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | - | - |
| P/S Ratio: | - | - |
| P/BV ratio: | - | - |
| P/CF Ratio: | - | - |
| PEG: | - | - |
| Earnings Yield: | - | - |
| Dividend Yield: | - | - |
| Market Capitalization | ||
| Market Capitalization: | 25.77 bill. USD | 0.0000 USD |
| Free Float Market Cap.: | - USD | - USD |
| Market Cap. / Employee: | - USD | - USD |
| Shares Outstanding: | - | |
Profitability
| Gross Profit Margin: | 80.48% |
| EBIT Margin: | 12.01% |
| Net Profit Margin: | 9.57% |
| Return on Equity: | 8.50% |
| Return on Assets: | 5.32% |
Financial Strength
| Liquidity I / Cash Ratio: | 45.97% |
| Liquidity II / Quick Ratio: | 105.94% |
| Liquidity III / Current Ratio: | 134.32% |
| Debt / Equity Ratio: | 59.72% |
| Dynam. Debt / Equity Ratio: | 338.75% |
Efficiency
| Employees: | 14,520 |
| Personal Expenses / Employee: | - JPY |
| Revenues / Employee: | 89,267,424.24 JPY |
| Net Income / Employee: | 8,545,867.77 JPY |
| Total Assets / Employee: | 160,633,264.46 JPY |
| * Fiscal Year End: | 2022-03-31 |
| Accounting Standard: | IFRS |
| Currency: | JPY |
